Build status - In Progress

Study to Assess Rifaximin Soluble Solid Dispersion (Ssd) Tablets for the Delay of Encephalopathy Decompensation in Cirrhosis (Red-C)

Recruiting
18 years - 85 years
All
10 participants needed
1 Location

Brief description of study

The purpose of this study is to see if a test medicine not yet approved for market, named Rifaximin SSD-40IR given Twice Daily, will help to delay the first episode of overt hepatic encephalopathy (OHE) requiring hospitalization, in patients with liver cirrhosis and how safe it is to use in people. Hepatic encephalopathy is a nervous system disorder caused by a buildup of toxins in the blood when the liver does not work properly. Participation in the study will last about 80 weeks, including the screening period which can last up to 28 days, followed by a 72-week treatment period and 4 week follow up period. This will involve 14 visits to be completed at the participant's study doctor’s clinic or at home every 4 to 8 weeks. Participants will be compensated $50.00 for each completed study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Liver,Cirrhosis
  • Age: 18 years - 85 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 851243

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center